Jacinta Abraham
YOU?
Author Swipe
View article: Subcutaneous Trastuzumab with Pertuzumab and Docetaxel in HER2-Positive Metastatic Breast Cancer: Final Analysis of MetaPHER, A Phase 3b Single-Arm Safety Study
Subcutaneous Trastuzumab with Pertuzumab and Docetaxel in HER2-Positive Metastatic Breast Cancer: Final Analysis of MetaPHER, A Phase 3b Single-Arm Safety Study Open
BACKGROUND Intravenous trastuzumab, pertuzumab, and docetaxel is first-line standard of care for patients with HER2-positive metastatic breast cancer. Subcutaneous trastuzumab plus intravenous pertuzumab and chemotherapy has shown similar …
View article: Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial Open
PURPOSE The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has …
View article: Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours
Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours Open
Background Tumour cells with BRCA1/2 gene mutations demonstrate increased sensitivity to platinum and poly (ADP-ribose) polymerase (PARP) inhibitors. 6-mercaptopurine (6MP) was found to selectively kill BRCA-defective cells in a xenograft …
View article: Supplementary Dataset For 'A Randomised Phase Iii Trial Of Carboplatin Compared With Docetaxel In Brca1/2 Mutated And Pre-Specified Triple Negative Breast Cancer "Brcaness" Subgroups: The Tnt Trial'
Supplementary Dataset For 'A Randomised Phase Iii Trial Of Carboplatin Compared With Docetaxel In Brca1/2 Mutated And Pre-Specified Triple Negative Breast Cancer "Brcaness" Subgroups: The Tnt Trial' Open
This dataset corresponds to the PAM50 gene expression profiling of primary tumour samples that were collected as part of the TNT clinical trial (ISRCTN97330959, NCT00532727, CRUK/07/012). NanoString® platform nCounter analysis was performe…
View article: Supplementary Dataset For 'A Randomised Phase Iii Trial Of Carboplatin Compared With Docetaxel In Brca1/2 Mutated And Pre-Specified Triple Negative Breast Cancer "Brcaness" Subgroups: The Tnt Trial'
Supplementary Dataset For 'A Randomised Phase Iii Trial Of Carboplatin Compared With Docetaxel In Brca1/2 Mutated And Pre-Specified Triple Negative Breast Cancer "Brcaness" Subgroups: The Tnt Trial' Open
This dataset corresponds to the PAM50 gene expression profiling of primary tumour samples that were collected as part of the TNT clinical trial (ISRCTN97330959, NCT00532727, CRUK/07/012). NanoString® platform nCounter analysis was performe…